Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Return on Capital Employed (2022 - 2025)

Historic Return on Capital Employed for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to 0.34%.

  • Taysha Gene Therapies' Return on Capital Employed rose 2000.0% to 0.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.34%, marking a year-over-year increase of 2000.0%. This contributed to the annual value of 0.65% for FY2024, which is 100.0% down from last year.
  • Per Taysha Gene Therapies' latest filing, its Return on Capital Employed stood at 0.34% for Q3 2025, which was up 2000.0% from 0.45% recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Return on Capital Employed registered a high of 2.64% during Q3 2023, and its lowest value of 2.92% during Q2 2023.
  • For the 4-year period, Taysha Gene Therapies' Return on Capital Employed averaged around 0.81%, with its median value being 0.59% (2024).
  • As far as peak fluctuations go, Taysha Gene Therapies' Return on Capital Employed soared by 24100bps in 2023, and later plummeted by -31800bps in 2024.
  • Taysha Gene Therapies' Return on Capital Employed (Quarter) stood at 2.9% in 2022, then skyrocketed by 83bps to 0.49% in 2023, then fell by -29bps to 0.63% in 2024, then surged by 46bps to 0.34% in 2025.
  • Its Return on Capital Employed stands at 0.34% for Q3 2025, versus 0.45% for Q2 2025 and 0.7% for Q1 2025.